Welcome to our dedicated page for Grifois news (Ticker: GRFS), a resource for investors and traders seeking the latest updates and insights on Grifois stock.
Grifols, S.A. reports developments tied to its global healthcare business, including plasma-derived medicines, diagnostic technologies, transfusion-medicine solutions and biological supplies for research, clinical trials and pharmaceutical or diagnostic manufacturing. Its business references include Biopharma, Diagnostic, Bio Supplies and other activities such as manufacturing services, research and complementary pharmaceutical products.
Recurring news themes include product and regulatory updates for plasma-protein therapies, such as fibrin sealant for surgical bleeding, and research programs that use plasma assets, AI, proteomics and real-world data. Coverage also includes Chronos-PD work led by Alkahest, shareholder communications on board composition and disclosure, and capital-market topics affecting Grifols' listed shares in Spain and the United States.
Grifols has finalized its agreement to acquire the remaining 56% of GigaGen for USD 80 million, strengthening its innovation strategy in biotherapeutics. GigaGen specializes in recombinant biotherapeutic medicines and has a promising pipeline, including GIGA-2050, an immunoglobulin for COVID-19, now entering Phase 1 trials in the U.S. The acquisition aligns with Grifols’ commitment to sustainable growth and expands its portfolio of advanced therapies, supporting patient health globally.
Grifols announced the launch of the world's first scientific journal dedicated to plasma science, coinciding with the 70th anniversary of the plasmapheresis technique. Titled Plasmatology, the journal aims to be the leading reference in plasma research, publishing peer-reviewed articles covering various topics in plasma science. Grifols will provide an educational grant over the next two years to support the journal's establishment. This initiative reinforces Grifols' commitment to research and scientific advancement in plasma-derived therapies, enhancing its leadership position in the industry.
Grifols, a leader in plasma-derived therapies, announced the launch of Plasmatology, the first scientific journal dedicated to plasma science, coinciding with the 70th anniversary of plasmapheresis. The journal, starting March 9, aims to become a key reference for plasma research and will publish peer-reviewed articles. Grifols will support the journal with an educational grant over two years. This initiative reflects the company's commitment to advancing plasma science and honors its founder's legacy in the field.
Grifols, a global leader in plasma-derived medicines, announced its PharmacyKeeper Verification software ranked No. 1 in IV Workflow Management in the 2021 Best in KLAS report, marking its fifth consecutive year at the top. This accolade reflects exceptional scores in quality, value, and ease of use across various healthcare facilities. Grifols has committed to supporting clients with COVID-19 vaccine workflows, showcasing its dedication to industry needs. The Best in KLAS rating, based on provider feedback, signifies Grifols' excellence in healthcare technology and services.
Grifols (NASDAQ: GRFS) has been recognized as the top vendor in IV Workflow Management for its PharmacyKeeper Verification software in the 2021 Best in KLAS report, marking its fifth consecutive year of receiving this accolade. This ranking reflects exceptional scores in quality, value, and user ease among a range of hospitals and systems. The company emphasizes its commitment to enhancing pharmacy operations, including a recent initiative to support COVID-19 vaccine preparation. Grifols is dedicated to safety and efficiency in healthcare settings through innovative solutions.
Grifols has announced a clinical trial set to commence in February 2021 in Spain to evaluate the safety and efficacy of a new COVID-19 treatment utilizing Gamunex®-C, which contains anti-SARS-CoV-2 polyclonal antibodies from recovered plasma donors. The trial will involve approximately 800 asymptomatic patients testing positive for the virus. This treatment is designed to offer immediate post-exposure protection, particularly for vulnerable populations. Results are anticipated in Spring 2021, with the potential to enhance existing vaccination efforts.
Summary not available.
Grifols (NASDAQ: GRFS) announced a partnership with TRC Healthcare on November 12, 2020, to enhance pharmacy education. This collaboration integrates Grifols' PharmacyKeeper, a leading IV Workflow Management system, with TRC's educational resources. The aim is to improve patient safety and care by providing pharmacists with up-to-date drug information and training. The partnership underscores Grifols' commitment to advancing IV room operations and reinforces its leadership position in the pharmacy technology market.
Grifols has commenced a randomized controlled clinical trial for its anti-SARS-CoV-2 hyperimmune globulin aimed at treating COVID-19. Funded by NIAID, this Phase 3 trial will assess safety, efficacy, and tolerability in 500 hospitalized adults across 58 hospitals in 18 countries. This treatment leverages convalescent plasma from recovered COVID-19 patients, potentially enhancing immune response to reduce severe illness risk. Grifols has quickly established a convalescent plasma collection program and is actively participating in over 25 COVID-19 initiatives.
Grifols has launched a clinical trial for its anti-SARS-CoV-2 hyperimmune globulin, aimed at treating COVID-19. This randomized controlled trial will assess the product's safety and efficacy in 500 hospitalized adults across 58 hospitals in 18 countries, including the U.S. and Spain. Funded by NIAID, the trial seeks to enhance immune responses when symptoms appear. Grifols leads multiple COVID-19 initiatives and has developed a robust plasma collection program to support treatment efforts during the pandemic.